Sanofi’s Dupixent Is Bucking Lockdown Trend, For Now
Physicians Adopting Telemedicine At Speed
Executive Summary
Its emerging flagship drug maintained rapid growth in Q1, but a longer lockdown will hit all competitors’ new prescriptions.
You may also be interested in...
GSK Plus Sanofi: The COVID-19 Vaccine Dream Team?
While not promising the fastest development time that the world craves, the combined experience and scale of the two vaccine giants bodes well.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.